Final Results From Phase 2 Study of Squalamine (OHR-102) in the Treatment of Age-Related Macular Degeneration (AMD) Will be Presented
NEW YORK, April 30, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, announced today the details of two podium presentations at the forthcoming Association for Research in Vision and Ophthalmology (ARVO) Conference, that will take place at the Colorado Convention Center in Denver, CO, May 3 – 7.
||Biodegradable Sustained-Release Drug Delivery Systems Fabricated using a Dissolvable Hydrogel Template Technology for the Treatment of Ocular Indications|
|Speaker:||Dr. Nikita Malavia|
|Location:||1EF Mile High Ballroom|
|Time||Monday, May 4 9:00am - 9:15am MDT|
||Final Results from a Phase 2 Study of Squalamine Lactate Ophthalmic Solution 0.2% (OHR-102) in the Treatment of Neovascular Age-related Macular Degeneration (AMD)|
|Speaker:||Dr. Jason Slakter|
|Location:||2-4 Four Seasons Ballroom|
|Time||Wednesday, May 06 5:00pm - 5:15pm MDT|
The Association for Research in Vision and Ophthalmology, Inc. (ARVO) was founded in 1928 in Washington, DC. ARVO's Annual Meetings has historically been the largest gathering of eye and vision researchers in the world, attracting over 11,000 attendees from more than 75 countries. The 2015 Annual Meeting will take place May 3-7 at the Colorado Convention Center, Denver CO. For more information, refer to www.arvo.org/Annual_Meeting/.
About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. is an ophthalmology research and development company whose lead product, Squalamine, is being studied as an eye drop formulation (OHR-102) in several company-sponsored and investigator sponsored clinical trials for various back-of-the-eye diseases. These diseases include the wet form of age-related macular degeneration, retinal vein occlusion, diabetic macular edema, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery. Additional information on the company may be found at www.ohrpharmaceutical.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as the date thereof, and Ohr Pharmaceutical undertakes no obligation to update or revise the forward-looking statement whether as a result of new information, future events or otherwise. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, the financial resources available to us, and general economic conditions. Shareholders and prospective investors are cautioned that no assurance of the efficacy of pharmaceutical products can be claimed or assured until final testing; and no assurance or warranty can be made that the FDA will approve final testing or marketing of any pharmaceutical product. Ohr's most recent Annual Report and subsequent Quarterly Report discuss some of the important risk factors that may affect our business, results of operations and financial condition.
CONTACT: Ohr Pharmaceutical Inc. Investor Relations 888-388-2327 email@example.com LifeSci Advisors, LLC Michael Wood 646-597-6983 firstname.lastname@example.orgSource: Ohr Pharmaceutical, Inc.